Determining when to switch from hydroxyurea to interferon-based therapy in patients with PV

Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, discusses considerations for community physicians when choosing between hydroxyurea and interferon therapy in patients with polycythemia vera (PV) and comments on when it may be necessary to switch between these therapies. Although hydroxyurea is attractive in its affordability and simplicity of administration, growing evidence suggests that interferon-based therapy may delay disease progression, potentially making it a better choice for certain patients. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Please note that if you are under 18, you won't be able to access this site.

Up next

Determining when to switch from hydroxyurea to interferon-based therapy in patients with PV

Up next

Language